From the Research
Denosumab is the most effective treatment option for osteoporosis in older adults, particularly those who are suboptimally adherent to alendronate therapy, as it significantly increases bone mineral density and reduces bone turnover markers compared to risedronate 1. When considering treatment options for osteoporosis, it is essential to individualize the selection based on factors such as underlying fracture risk, medical comorbidities, medication burden, and fracture risk reduction profiles, modes of administration, and side effects of treatment options 2. Key considerations for osteoporosis treatment include:
- Polypharmacy is associated with worse adherence to pharmacologic therapy, making it crucial to select treatments with simple administration regimens 2
- Denosumab has been shown to be more effective than risedronate in increasing bone mineral density and reducing bone turnover markers in postmenopausal women who are suboptimally adherent to alendronate therapy 1
- Real-world studies have demonstrated that denosumab persistence and reinitiation rates vary between populations, highlighting the need for tailored treatment strategies and improved patient education 3
- Effective management of diagnostic uncertainty is critical in the diagnostic process, and strategies such as acknowledging uncertainty, obtaining more contextual information, and communicating diagnostic uncertainty to patients can help facilitate accurate and timely diagnoses and treatments 4